Arca
Skip to content
Tools
Tools

S: Spike glycoprotein

Protein in Severe acute respiratory syndrome coronavirus 2 that 20 drugs act on.

  • Drugs that act on it: 20
  • Approved: 8
  • In phases 1 to 3: 12
  • Sponsors: 11

Who is on it, and how far along

Every drug ChEMBL records acting on S, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 12
  • Protein or peptide 2
  • Other 6

Approved8

Phase 39

  • Casirivimab
  • Imdevimab
  • Bamlanivimab
  • Cilgavimab
  • Tixagevimab
  • Amubarvimab
  • Ensovibep
  • Etesevimab
  • Romlusevimab

Phase 23

  • Abdavomeran
  • Adintrevimab
  • Bebtelovimab

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Pregistry315%
    • Brii Biosciences Limited210%
    • MediMergent, LLC210%
    • BioNTech SE15%
    • BMI Korea15%
    • Cellid Co., Ltd.15%
    • ModernaTX, Inc.15%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 11 of 20 act as: Spike glycoprotein inhibitor; the rest name their own mechanism.
    SARS-COV-2 virus spike proteinApprovedBMI KoreaVaccine componentVaccine antigenSpike glycoprotein vaccine antigen12
    ElasomeranApprovedModernaTX, Inc.OligonucleotideVaccine antigenSpike glycoprotein vaccine antigen6
    SotrovimabApprovedPregistryAntibodyInhibitor4
    TozinameranApprovedCellid Co., Ltd.Vaccine componentVaccine antigenSpike glycoprotein vaccine antigen4
    Chimpanzee adenovirus encoding SARS-COV-2 spike glycoproteinApproved—Vaccine componentVaccine antigenSpike glycoprotein vaccine antigen1
    Adenovirus type 26 encoding SARS-COV-2 spike glycoproteinApproved—Vaccine componentVaccine antigenSpike glycoprotein vaccine antigen0
    RegdanvimabApprovedCelltrionAntibodyInhibitor0
    SelvacovateinApproved—Protein or peptideVaccine antigenSpike glycoprotein vaccine antigen0
    CasirivimabPhase 3PregistryAntibodyInhibitor4
    ImdevimabPhase 3PregistryAntibodyInhibitor4
    BamlanivimabPhase 3—AntibodyInhibitor1
    CilgavimabPhase 3MediMergent, LLCAntibodyBlockerSpike glycoprotein blocker1
    TixagevimabPhase 3MediMergent, LLCAntibodyBlockerSpike glycoprotein blocker1
    AmubarvimabPhase 3Brii Biosciences LimitedAntibodyInhibitor0
    EnsovibepPhase 3Molecular PartnersProtein or peptideInhibitor0
    EtesevimabPhase 3—AntibodyInhibitor0
    RomlusevimabPhase 3Brii Biosciences LimitedAntibodyInhibitor0
    AbdavomeranPhase 2BioNTech SEOligonucleotideVaccine antigenSpike glycoprotein vaccine antigen0
    AdintrevimabPhase 2InvivydAntibodyInhibitor0
    BebtelovimabPhase 2Eli LillyAntibodyInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 22 in all, from ClinicalTrials.gov.
    Safety, Tolerability, and Immunogenicity of BMI2012 Against COVID-19 Variant in Healthy Adults Aged 19 and 55 YearsSARS-COV-2 virus spike proteinPhase 1Not yet recruitingBMI KoreaAug 27, 2026
    A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of AgeSARS-COV-2 virus spike proteinPhase 4RecruitingBioNTech SEJul 28, 2026
    A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 VaccineSARS-COV-2 virus spike proteinPhase 1Not yet recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Jul 14, 2026
    Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in PneumoniaSARS-COV-2 virus spike proteinPhase 2Not yet recruitingNational Research Institute of Chinese Medicine, Ministry of Health and WelfareMay 13, 2026
    A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated AdultsChimpanzee adenovirus encoding SARS-COV-2 spike glycoprotein, SARS-COV-2 virus spike proteinPhase 1Active, not recruitingNational Institute of Allergy and Infectious Diseases (NIAID)Apr 17, 2026
    Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant PatientsTozinameranPhase 2Not yet recruitingFred Hutchinson Cancer CenterFeb 5, 2026
    A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.SARS-COV-2 virus spike proteinPhase 1 / Phase 2Active, not recruitingSK Bioscience Co., Ltd.Dec 12, 2025
    A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19SARS-COV-2 virus spike proteinPhase 1Active, not recruitingUniversity of MelbourneMay 11, 2025
    Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.ElasomeranPhase 4RecruitingWell- Konnect Healthcare Services and Research FirmJun 4, 2024
    Covid-19 and Influenza Oral Vaccine StudySARS-COV-2 virus spike proteinPhase 1RecruitingVaxine Pty LtdApr 9, 2024
    Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGEElasomeran—Active, not recruitingModernaTX, Inc.Mar 27, 2024
    Immunogenicity and Safety of AdCLD-CoV19-1 OMI As a Booster: a COVID-19 Preventive Vaccine in Healthy VolunteersTozinameranPhase 3Active, not recruitingCellid Co., Ltd.Aug 15, 2023
    COVID-19 Booster Study in Healthy Adults in AustraliaElasomeranPhase 3Active, not recruitingMurdoch Childrens Research InstituteDec 20, 2022
    Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical TrialElasomeran, TozinameranPhase 3Active, not recruitingMonash UniversitySep 27, 2022
    The Impact of COVID-19 on Maternal and Neonatal OutcomesElasomeran—RecruitingJohns Hopkins UniversityJan 19, 2022
    Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)Casirivimab, Cilgavimab, Imdevimab, Sotrovimab, TixagevimabPhase 2RecruitingUniversity of OxfordSep 13, 2021
    Korea Comirnaty Post-marketing SurveillanceTozinameran—Active, not recruitingPfizerSep 2, 2021
    COVID-19 International Drug Pregnancy RegistryCasirivimab, Imdevimab, Sotrovimab—RecruitingPregistryAug 19, 2021
    COVID-19 Vaccines Safety Tracking (CoVaST)Elasomeran—RecruitingMasaryk UniversityApr 8, 2021
    Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)Bamlanivimab, Casirivimab, ImdevimabPhase 1 / Phase 2RecruitingAll Natural Medicine Clinic, LLCMar 10, 2021
    AGILE (Early Phase Platform Trial for COVID-19)SotrovimabPhase 1 / Phase 2RecruitingUniversity of LiverpoolFeb 9, 2021
    Randomised Evaluation of COVID-19 TherapyCasirivimab, Imdevimab, SotrovimabPhase 3RecruitingUniversity of OxfordMay 11, 2020

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4662936, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.